1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F19%3A43919044" target="_blank" >RIV/60461373:22340/19:43919044 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer
Original language description
Pancreatic cancer (PC) has very high mortality, only 5% of patientssurvive longer than 3–5 years, this is mostly due to late diagnosis.1Nowadays, the PC diagnosis is mainly limited by non-specific earlysymptoms (weakness, nausea, or abdominal pain) and methods withlow sensitivity and specificity.2Consequently, early specific symptomsand characteristic biomarkers remain a subject of intensive research.In our study,1H NMR metabolomics was used to identify changesin the concentration of low molecular metabolites in the blood plasmaof healthy controls, pancreatic cancer patients, long term type 2 dia-betes mellitus patients and individuals with new-onset diabetes. UsingChenomX software, it was possible to quantify 65 metabolites acrossall samples. Subsequently, a statistical analysis (PCA, OPLS-DA,
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
10406 - Analytical chemistry
Result continuities
Project
<a href="/en/project/NV16-31028A" target="_blank" >NV16-31028A: Efficacy of new spectroscopic biomarkers for detection of early stage pancreatic cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů